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Small molecule aggregators form aggregates or colloids at micromolar concentrations in buffered solutions. 1 Aggregators are commonly found and widely distributed within large compound libraries. 2 These compounds are frequently identified as inhibitors, and they are often prevalent early in drug discovery campaigns. 3 Such compounds may be problematic to identify as false positive because the mechanism by which they inhibit target proteins and enzymes is nonspecific, producing results similar to true positives in a variety of assays. 4 There are hallmarks for aggregator-based inhibition. Aggregators often show non-competitive inhibition, 5 as well as slowly reversible, 6 and time-dependent inhibition. 7 Of course, true positives can also show these characteristics. However, more particular to aggregators, inhibitor potency as indicated by the kinetic parameters of inhibition, often varies with enzyme concentration. 7 Detergents often reduce or even eliminate inhibition by aggregate-forming false positives. 8 In addition, these compounds are non-specific, 9 inhibiting multiple unrelated enzymes, [10] [11] [12] and they show dose-response curves with high Hill slopes. 13 Structure-activity relationships (SAR) may be ambiguous 14 . Finally, particles of varying sizes may be detected in aqueous solutions containing these compounds. 15, 16 Fourteen compounds containing oxadiazole-amide (Table 1) and aminobenzothiazole scaffolds (Table 2) were evaluated in this study. These compounds originated from a library of 404 compounds selected through the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) Program of the National Institute of Allergy and Infectious Diseases (NIAID). This set of 404 compounds were in M. tuberculosis H37Rv screens performed at Southern Research Institute (SRI). [17] [18] [19] The collection was further tested in vitro against M. tuberculosis shikimate kinase (MtSK). Out of 404 compounds 14 hits displayed >90 % inhibition at concentrations below 50 µM. 20 In this study, we investigated aggregate forming properties of compounds in the 14 MtSK hit set, utilizing ESI-LC-MS, proton nuclear magnetic resonance spectroscopy ( 1 H-NMR), dynamic light scattering (DLS), transmission electronic microscopy (TEM). Centrifugation assays were utilized to detect precipitate formation and qualitatively determine the solubility of compounds. The tendency of these compounds to form aggregates was predicted computationally, using the aggregate advisor tool and MycPermCheck software. We have used two controls. The MtSK-specific inhibitor, 3-methoxy-4-{[2-({2-methoxy-4-[(4-oxo-2-thioxo-1,3thiazolidin5ylidene)methyl] phenoxy}methyl)benzyl]oxy}ben-zaldehyde (Fig. S1 ) was utilized in all experiments except 1 H-NMR. Riluzole, a nonaggregator (Fig. S3 ), was used in 1 H-NMR assays.
Single dose high-throughput screening (HTS) followed by dose-response evaluations is a common strategy for the identification of initial hits for further development. Early identification and exclusion of false positives is a cost-saving and essential step in early drug discovery. One of the mechanisms of false positive compounds is the formation of aggregates in assays. This study evaluates the mechanism(s) of inhibition of a set of 14 compounds identified previously as actives in Mycobacterium tuberculosis (Mt) cell culture screening and in vitro actives in Mt shikimate kinase (MtSK) assay. Aggregation of hit compounds was characterized using multiple experimental methods, LC-MS, 1 H-NMR, dynamic light scattering (DLS), transmission electron microscopy (TEM), and visual inspection after centrifugation for orthogonal confirmation. Our results suggest that the investigated compounds containing oxadiazole-amide and aminobenzothiazole moieties are false positive hits and non-specific inhibitors of MtSK through aggregate formation. 2009 Elsevier Ltd. All rights reserved.
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Compared to reactions that contained only MtSK and its substrates, inclusion of any one of the compounds resulted in a substantial decrease in S3P production (Table 3) as observed in extracted ion chromatograms (Fig. 1 ), This indicates inhibition; however, the inhibitory effect was completely eliminated if Triton X-100 was also present or if MtSK concentration in the assays was increased from 0.02 to 0.2 μM. These data indicate that inhibition by these compounds is due, at least in part, to their propensity to form aggregates that non-specifically disrupt MtSK structure. Accordingly, inclusion of Triton X-100 limits formation of aggregates, and therefore, eliminates that contribution to MtSK inhibition. Likewise, inhibition by aggregators is known to be attenuated by an increase in enzyme concentration. Consistent with these findings, inhibition by a known specific inhibitor of MtSK as a control was not eliminated either by the inclusion of detergent or increasing the concentration of MtSK in activity assays. Interestingly, even the control showed potential signs of aggregation, albeit to a much lesser extent than the other compounds. Addition of Triton X-100 increased % inhibition by the control when the concentration of MtSK was 0.2 μM. One explanation is that aggregation was disrupted in the biochemical buffer, permitting the control to behave as a specific inhibitor in the classical sense. With all compounds, a sharp transition to full inhibition occurred over a very narrow range of concentration (Fig. 2) as reflected by Hill coefficients substantially greater than 1. This is a common pattern among non-specific inhibitors. 20 which showed similar phenomenon to compound 3 in this study. Notably, the control exhibited a similarly steep Hillslope, this is likely due to the presence of aggregates at higher concentration. The effect of Triton X-100 addition to 0.2 mM MtSK experiments in Table 3 supports this conclusion. Table 5 lists computed cLogP (partition coefficient) and LogS (solubility) for the fourteen compounds (Schrödinger software). Computed parameters suggest that compound 11 is the most lipophilic (cLogP 5.148) whereas compound 4 the least hydrophobic (cLogP 1.736). Within this set compound 2 is predicted as least soluble (solubility: -6.854) and compound 9 as most soluble (solubility: -4.246).
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With the MycPermCheck tool, Mtb cell wall permeability was predicted for the set of fourteen compounds based on four descriptors listed in Table 6 . The predicted permeability was color coded as follows: high permeability scores are colored green (0.82 < score < 1), medium permeability orange (0.55 < score < 0.82) and poor permeability red (score < 0.55). Interestingly, eight compounds were predicted to be highly permeable, namely, 2, 3, 6, 7, 9, 11, 13, and 14. These compounds are also associated with higher LogP values within the set. Considering one descriptor only will not guarantee high permeability values. Instead, all descriptors should be taken into consideration. As described by Merget et al., 21 the computational tool predicts passive diffusion transportation only, which is a limitation of the tool, this suggests that compounds 1, 4, 5, 8, 10, and 12 traverse Mtb cell wall by other mechanisms. Although the permeability prediction tool is useful for predicting compounds that are expressing their activity through cell wall penetration, absolute confirmation is not expected. Therefore, we suggest that, from the set of 14 compounds, the most active compounds, 4, 6, 7, 8, 9, 11, and 14 (Table 7) should be further investigated so as to understand their mechanism of action. Table 4 . IC50 values of non-specific inhibitors against 0.015 μM purified MtSK. Table 6 . Mtb cell wall permeability prediction of oxadiazole-amide and 2-aminobenzothiazole compounds. Table 7 . Anti-Mtb phenotypic activity of oxadiazole-amide and 2-aminobenzothiazole For the evaluation of micelle formation, we selected compound 9, which was predicted most soluble among the fourteen compounds. Protons attached to the methyl and ethyl groups present in its aliphatic side chain (see Fig. S2 ) were selected to monitor peak broadening since these were easily recognized and differentiated in 1 H NMR spectra. Moreover, the aliphatic chain is lipophilic and may contribute to the formation of aggregates of this compound in the buffer solution.
An increasing contribution from peak broadening was observed in 1 H-NMR spectra with increasing concentration of 9 from 6.25 µM up to 200 µM (Fig 3A) , indicating aggregate formation. The MtSK inhibitory potency of compound 9 was previously determined in our laboratory 20 and reported having the IC 50 value of 20.73 µM.
1 H NMR spectra of compound 9 in Fig.  3A showed peak broadening (aggregation) even at 6.25 µM, which indicates that MtSK inhibition by compound 9 was nonspecific, likely due to formation of aggregates. In contrast, riluzole (Fig. S3) , a glutamate blocker for treatment of amyotrophic lateral sclerosis 22 and a known non-aggregator, 23 showed no peak broadening across a concentration range from 12.5 -200 µM (Fig. 3B) . Signal intensities displayed sharp resonance and a gradual reduction of signal intensity in alignment with the compound dilution. No signal shifts were observed. Normal NMR resonances should be sharp, and shift in signals should not be expected. There should be no changes in the number and shape of the resonances should be constant.
We obtained two parameters from our DLS studies, intensity of scattered light and average particle size, both of which increase when aggregation occurs. Compounds 1-14 at 100 µM were dissolved in two media, ammonium acetate buffer (Table 8 ) and water (Table S1 ). In either solution, scattering intensity and particle size were both large, suggesting aggregation. In comparison, when 0.01% Triton X-100 was also included, light scattering intensity and particle size were both substantially diminished, indicating dissolution of aggregates formed by these compounds. Indeed, in ammonium acetate the average test compound at 100 µM showed a scattering intensity of 292 k count and particle size of 1731 nm in the absence of Triton X-100. Conversely, in the presence of 0.01% Triton X-100, they displayed an average scattering intensity of 136 k count and particle size of 343 nm. Nearly identical results were observed in water (Table S1 ). These phenomena were in stark contrast with 3-methoxy-4-{[2-({2-methoxy-4-[(4-oxo-2-thioxo-1,3thiazolidin5ylidene)methyl]phenoxy}methyl)benzyl]oxy}ben -zaldehyde, the MtSK-specific control inhibitor, which did not scatter light and did not form particles in either medium until a concentration of 30 µM (three-fold higher than the IC 50 from Fig. 2 ). This may be indicative of some aggregation, but even under these conditions both k count and particle size were substantially smaller than the 14 test compounds. To corroborate our DLS investigation, we used transmission electron microscopy (TEM) to image particles formed by each of our 14 candidate compounds in aqueous ammonium acetate. The behavior of compound 14 was typical ( Fig. 4A and B) . In the absence of Triton X-100, large aggregates were observed (mean size = 0.7µm) (Fig. 4A) ; however, when Triton X-100 was added, the aggregates were disintegrated, producing particle sizes in the submicron range (Fig. 4B) . This confirms the tendency of the compounds toward aggregation and the interference of a detergent like Triton X-100 in that process. At 30 µM, the control exhibited smaller particle size (mean = 0.1µm) (Fig. 4C) . Inclusion of Triton X-100 resulted in the dissolution of aggregates, producing a mean size particle of 0.005 µm (Fig. 4D ). When each of the fourteen compounds (50 and 100 M in buffered solution) was subjected to centrifugation (14,000  g for 40 min.), pellets were evident by visual inspection (data not shown).
Among the fourteen compounds, 1, 2, 3, 5, 6, 7, 8, 9 , 10, and 13 were predicted to form aggregates or micelles, based on the aggregator advisor tool database. Compound 1 had the highest percentage, 93% of similarity to a previously reported aggregator, whereas compounds 8 and 13 had the lomtwest, 72% of similarity within the set. Although compounds 11, 12, 14, and the MtSK-specific inhibitor control did not resemble any previously described aggregator in the aggregator advisor tool database, 24 these were flagged as potential aggregators and suggested for experimental evaluation. Our results clearly show that 14 (Fig. 4) as well as 11 and 12 (Table 8) form aggregates. However, the MtSK-specific control inhibitor showed only a limited capacity to form aggregates (Fig. 4) and (Table 8) , and this was at a concentration three-fold greater than the IC 50 . Aggregation is a likely contributor to inhibition of MtSK by 14 (see Fig. 4 ). Compound 4 was the only compound from the list that was not flagged. Nevertheless, our approach was able to identify even 4 as an aggregating inhibitor.
An interesting aspect of the fourteen compounds investigated here is that all of them have IC 90 values < 4 μg/ml in M. tuberculosis H37Rv whole-cell screens (Table 7) . [17] [18] [19] At first glance, this is at variance with the data we present here, showing the strong propensity of all of these compounds to form aggregates and inhibit MtSK on that basis. However, taken together, these data reveal two important conclusions. First, it is likely that complex biological media/intact cells contain certain proteins or other factors that ameliorate aggregate formation or otherwise facilitate compound delivery to the intracellular milieu. This is consistent with what has been noted elsewhere for some known drugs 5 and confirms that a tendency toward aggregation need not be a death sentence for drug development. Second, it seems clear that the antitubercular properties of these compounds are due to their interaction with a target(s) other than MtSK.
In this study, fourteen compounds, oxadiazole-amides and 2-aminobenzothiazole, have been characterized as non-specific inhibitors of MtSK due to aggregation. This phenomenon was observed across a variety of techniques, including LC-MS, 1 H-NMR, DLS, TEM, and centrifugation assays. In general, these assays should serve as practical tools to eliminate false positive hits in early drug discovery process. Detection of promiscuous inhibitors early on saves time and resources. We propose the use of LC-MS and NMR based assays to detect aggregation produced by false positive compounds. These methods are widely used in inhibition studies and routinely available in drug discovery and development laboratories.
